Despite available treatments, there is still an unmet need to improve outcomes for some patients with myelodysplastic syndrome, or MDS. Thankfully, there is a wide array of therapies in development that could fill this gap, but which therapies can we start to consider as real future options for which patients? To answer our questions on this topic, we’ve invited the expertise of invited Dr Amer Zeidan, Associate Professor of Internal Medicine, Hematology, at the Yale University School of Medicine.
References
- @Dr_AmerZeidan
- Swords, et al. Blood. 2018;131(13):1415-1424
- Ades, et al. ASCO 2020. Abstract 7506
- Swoboda, et al. Curr Opin Hematol. 2020 Mar; 27(2): 58-65
- Germing, et al. Expert Rev Hematol. 2019; 12(10): 893-908
- Fenaux, et al. N Engl J Med. 2020 Jan 9; 382(2): 140-151
- Vousden & Lu. Nat Rev Cancer. 2002 Aug; 2(8): 594-604
- Lindberg, et al. Haematologica. 2020 Jul; 105(7): 1765–1779
- Braun, et al. Cells. 2020 Jun 26; 9(6): 1559
- Platzbecker, et al. EHA Library. 2020; 295003; S183
- Hamed. Canc Therapy & Oncol Int J.2019; 13(5): 1-4
- Ravandi, et al. Lancet Haematol. 2019 Sep; 6(9): e480-e488
This independent educational activity is supported by an educational grant from Servier Pharmaceuticals LLC and Takeda. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Servier and Takeda have had no influence on the content of this education.